Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
5 studies found for:    12637609 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Unknown  Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Imatinib
2 Recruiting Nilotinib-Chemotherapy in CML Myeloid BP or Bcr-abl(+) AML
Conditions: Chronic Myeloid Leukemia in Myeloid Blast Crisis;   Untreated Adult Acute Myeloid Leukemia
Intervention: Drug: Nilotinib+AD induction
3 Unknown  Allogeneic Stem Cell Transplantation in CML With Partial T Cell Depletion
Condition: Philadelphia Chromosome-positive Chronic Myelocytic Leukemia
Intervention: Procedure: Stem cell transplantation
4 Completed Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia
Condition: Chronic Myeloid Leukaemia
Interventions: Drug: Glivec;   Drug: Interferon
5 Completed STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
Condition: Leukemia
Interventions: Biological: recombinant interferon alfa;   Drug: cytarabine;   Drug: imatinib mesylate

Indicates status has not been verified in more than two years